Table 6.

Restricted mean survival time to achieve maximum pain relief and restricted mean time lost for pain-free time from the categorical pain relief scale (PRS).

Scale	Group	Subjects (n)		Τime (min)	RMST ± SE (95% CI) (min)	RMTL ± SE (95% CI) (min)	Between-group mean survival comparison
		Symptom resolved	Total				RMST difference (95% CI) (min) (P-TBF)	RMST ratio (95% CI) (P/TBF)	RMTL ratio (95% CI) (P/TBF)	P
PRS on rest	TBF	108	116	360	194 ± 7.40 (179.5–208.5)	166 ± 7.40 (151.5–180.5)	151.5 ± 8.94 (134–169)	1.78 ± 0.04(1.64–1.93)	0.09 ± 0.35(0.04–0.17)	<.0001*
										<.0001†
	Placebo	11	116	360	345.5 ± 5.01 (335.7–355.3)	14.5 ± 5.01 (4.7–24.3)				<.0001‡
PRS on movement	TBF	114	116	360	197.7 ± 7.40 (183.2–212.2)	162.3 ± 7.40 (147.8–176.8)	155.5 ± 8.03(139.8–171.2)	1.79 ± 0.04 (1.66–1.93)	0.04 ± 0.46 (0.02–0.1)	<.0001*
										<.0001†
	Placebo	9	116	360	353.2 ± 3.10(347.1–359.3)	6.8 ± 3.10 (0.7–12.9)				<.0001‡
PRS on pressure	TBF	110	116	363	194.2 ± 7.58 (179.3–209)	168.8 ± 7.58 (154–183.7)	162.6 ± 8.18 (146.5–178.6)	1.84 ± 0.04 (1.7–1.99)	0.04 ± 0.49 (0.01–0.1)	<.0001*
										<.0001†
	Placebo	8	116	363	356.7 ± 3.08 (350.7–362.8)	6.3 ± 3.08 (0.2–12.3)				<.0001‡

P = placebo; RMST = restricted mean survival time to maximum pain relief; RMTL = restricted mean time lost to maximum pain relief; TBF = turmeric-boswellia formulation.

^*Between-group P-value of RMST difference.

^†Between-group P-value of RMST ratio.

^‡Between-group P-value of RMTL ratio.